![](/accounts/npace/images/logo.jpg)
(DEA) MATE Act - Substance Use Disorder Bundle V2
-
Register
- User - $225
In accordance with the Medication Access and Training Expansion (MATE) Act, beginning June 7, 2023, all providers who are registered with the DEA are required to complete 8 hours of training on the treatment and management of patients with opioid and other substance use disorders. This bundle fully satisfies this one-time requirement.
Total Credits: 9.00 contact hours; 8.5 are pharmacology
Expiration Date: June 30, 2025
$225
-
Includes Credits
Opioid prescribing has been highly scrutinized in the US over the last 10 yrs. Yet, patients continue to present to primary care with complaints of pain. Opioids remain a cornerstone of treatment. This session will focus on how and when it is appropriate to prescribe opioids in primary care. | 1.50 credits (1.50 Pharmacology) | $40
-
Includes Credits
This presentation will focus on non-opioid therapies for the treatment of both acute and chronic pain. With such scrutiny into pain practice over the last few years, providers need to arm themselves with appropriate therapies for pain. What patient, when and how will be discussed in this section. | 1.50 credits (1.50 pharmacology) | $40.00
-
Includes Credits
Alcohol, marijuana, and tobacco are substances most commonly used by adolescents. Substance use in adolescence becomes risky, when does substance use become substance abuse? This presentation will focus on adolescent substance use and abuse. This presentation will also focus on the most commonly abused substances during adolescence, factors that contribute to substance abuse and treatment plans. | 1.50 credits (1.50 pharmacology) | $40
-
Includes Credits
Adolescent substance use has followed familiar trends for several decades with alcohol, nicotine, and cannabis leading other drugs in popularity. After several years of declining nicotine use, primarily via combustible cigarettes, recent data suggests a resurgence of nicotine use, primarily via e-cigarettes as well as a marked increase in cannabis use, likely corresponding with legalization efforts. Additionally, there has been an increase in hallucinogen use and the dangers of opioid use have heightened due to the rise of illicit fentanyl being brought in from outside the United States. This lecture will review the most recent Monitoring the Future study and discuss implications of adolescent substance use trends on healthcare providers. | 1.50 credits (1.50 Pharmacology) | $40
-
Includes Credits
During the last 20 years, the rules and regulations regarding pain, opioid prescribing and opioid use disorder have changed significantly. Attendees will be taught the latest and most up-to-date information on DEA’s authority and background, licensing, registration, drug diversion, telemedicine, medication assistance treatment, nationwide opioid prescribing guidelines and case studies, along with learning risk mitigation strategies and best practices that will safeguard their practices. The instructor is a former DEA Special Agent with over 30 years of public service with real life prescription opioid experience. | 1.50 credits (1.00 Pharmacology) | $40
-
Includes Credits
The ongoing opioid epidemic has led to controversy regarding the appropriate treatment of both acute and chronic forms of pain. Avoidance of opioids has led to the potential for inadequate pain management and a potential for increased adverse events related to non-opioid analgesics, specifically NSAIDs. The CDC updated their guidelines for prescribing opioids with the hope of providing more guidance for practitioners about how to safely utilizing these medications. Novel therapies are also being explored as an alternative to opioids and one promising medication is intravenous ketamine. This presentation will review updated guidelines to help determine when and how to safely utilize both opioid and non-opioid analgesics. Additionally, it will explore the potential of IV ketamine for acute pain management. | 1.50 credits (1.50 Pharmacology) | $40